PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32312713-11	2020	22 had significant ERalpha gene expression changes (<0.5 or >2.0) with 7/10 increases in placebo and 10/12 decreases for SDG (P=0.028), and a difference between arms (P =0.017).	secoisolariciresinol diglucoside	121-124	estrogen receptor 1	Homo sapiens	19-26	
30367332-1	2019	PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERalpha)-negative disease, and decreased preclinical mammary tumor growth.	secoisolariciresinol diglucoside	51-83	estrogen receptor 1	Homo sapiens	206-229	
30367332-1	2019	PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERalpha)-negative disease, and decreased preclinical mammary tumor growth.	secoisolariciresinol diglucoside	51-83	estrogen receptor 1	Homo sapiens	231-238	
30367332-1	2019	PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERalpha)-negative disease, and decreased preclinical mammary tumor growth.	secoisolariciresinol diglucoside	85-88	estrogen receptor 1	Homo sapiens	206-229	
30367332-1	2019	PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERalpha)-negative disease, and decreased preclinical mammary tumor growth.	secoisolariciresinol diglucoside	85-88	estrogen receptor 1	Homo sapiens	231-238	
19904759-1	2010	This study aimed to elucidate which component of flaxseed, i.e. secoisolariciresinol diglucoside (SDG) lignan or flaxseed oil (FO), makes tamoxifen (TAM) more effective in reducing growth of established estrogen receptor positive breast tumors (MCF-7) at low circulating estrogen levels, and potential mechanisms of action.	secoisolariciresinol diglucoside	64-96	estrogen receptor 1	Homo sapiens	203-220	
19904759-1	2010	This study aimed to elucidate which component of flaxseed, i.e. secoisolariciresinol diglucoside (SDG) lignan or flaxseed oil (FO), makes tamoxifen (TAM) more effective in reducing growth of established estrogen receptor positive breast tumors (MCF-7) at low circulating estrogen levels, and potential mechanisms of action.	secoisolariciresinol diglucoside	98-101	estrogen receptor 1	Homo sapiens	203-220	
20432175-7	2010	SDG alone also lowered the ERalpha, ERbeta, EGFR, BCL2 mRNA, and PMAPK protein, indicating that its effect involves the modulation of the ER- and growth factor receptor-mediated signaling pathways.	secoisolariciresinol diglucoside	0-3	estrogen receptor 1	Homo sapiens	27-34